There are currently three checkpoint inhibitors that targeted PD-1/PD-L1 and are approved for lung cancer: nivolumab (Opdivo), pembrolizumab (Keytruda), and atezolizumab (Tecentriq) (6). The gene discussed is CD274; the disease is lung carcinoma.